Kyprolis (Carfilzomib)

What it is and what it treats

Carfilzomib is a tetrapeptide epoxyketone that irreversibly inhibits the chymotrypsin-like activity of the 20S proteasome, a key component of the cellular pathway that degrades misfolded proteins. Its irreversible binding produces sustained proteasome inhibition, leading to accumulation of misfolded proteins, endoplasmic reticulum stress, and apoptosis, particularly in rapidly dividing myeloma cells with high protein turnover.

Kyprolis is authorised for use in patients with relapsed or refractory multiple myeloma, typically in combination with dexamethasone alone or with lenalidomide and dexamethasone, in patients who have received at least one prior line of therapy. Treatment decisions are made by a haematologist based on prior treatment history, cytogenetic risk and organ function.

As a second-generation proteasome inhibitor, carfilzomib is often considered when a first-generation agent such as bortezomib has been discontinued because of peripheral neuropathy or has produced an inadequate response, though the choice between agents depends on individual patient factors including cardiovascular history.

Presentations and dosage forms

• Powder for solution for infusion, 10 mg, 30 mg and 60 mg vials
• Single-use vials for intravenous administration after reconstitution
• Supplied for use within combination regimens with dexamethasone or lenalidomide and dexamethasone

How it is administered

The EU SmPC describes carfilzomib as given by intravenous infusion over 10 to 30 minutes, on specific days of a 28-day cycle, with dosing typically beginning at a lower level in cycle one before stepping up in subsequent cycles to reduce the incidence of infusion-related reactions.

Pre-hydration and, in some regimens, pre-medication with a corticosteroid are described in the label to reduce the risk of infusion reactions and tumour lysis syndrome. The infusion schedule and concomitant regimen (with dexamethasone, or with lenalidomide and dexamethasone) are determined by the prescribing haematologist.

Because cardiac adverse events, including heart failure and arrhythmias, have been described with carfilzomib, baseline cardiac assessment and monitoring of blood pressure throughout treatment are part of the recommended clinical approach; dose modification or interruption is managed according to the physician's assessment of tolerability.

Storage and handling

• Store unopened vials at 2–8 °C in the original carton, protected from light
• Do not freeze
• After reconstitution, the solution has a defined in-use stability period at refrigerated and at room temperature described in the SmPC
• Requires validated cold-chain transport with continuous temperature monitoring
• Discard any reconstituted solution beyond the stated stability window

Side effects

The following adverse reactions are described in the approved EU SmPC and FDA prescribing information for carfilzomib.

Commonly reported

Serious effects requiring medical attention

Patients should report new or worsening shortness of breath, chest pain, swelling or palpitations promptly, as these may indicate a cardiac or pulmonary adverse event requiring assessment. Suspected adverse reactions should be reported through national pharmacovigilance systems.

Kyprolis (carfilzomib) compared with bortezomib

Bortezomib was the first proteasome inhibitor approved for multiple myeloma and remains widely used, particularly given its subcutaneous administration option and extensive clinical experience. It binds the proteasome reversibly, which is associated with a comparatively higher incidence of peripheral neuropathy, a side effect that can limit long-term use and quality of life.

Carfilzomib's irreversible binding produces more sustained proteasome inhibition and, in comparative trials, has been associated with a lower rate of peripheral neuropathy than bortezomib. However, carfilzomib is administered only intravenously and carries a distinct cardiovascular safety profile, including reports of hypertension, cardiac failure and pulmonary hypertension, which requires baseline and on-treatment cardiac monitoring that is not routinely needed with bortezomib.

The choice between the two agents, or their use in sequence, depends on factors such as pre-existing neuropathy, cardiac history, prior treatment exposure and patient preference regarding route of administration, and is made by the treating haematologist rather than being a straightforward substitution.

Availability and supply route

Registration of Kyprolis and its approved indications varies between countries. Hospitals and prescribers should verify current local authorisation status, funding arrangements and approved combination regimens with the relevant national medicines authority.

In countries where carfilzomib is not registered, or where local supply is interrupted, institutions may pursue named-patient or unlicensed-medicine import routes, whereby a licensed wholesaler sources a specific product against a named patient's prescription in line with the destination country's import regulations.

Pharmacy Remedy is a licensed Turkish pharmaceutical wholesaler supplying hospitals, clinics and licensed pharmacies through verified institutional channels. It operates within wholesale distribution and named-patient supply regulations and does not sell medicines directly to the public.

Frequently asked questions

Primary sources

• EMA — Kyprolis EPAR
• FDA — Kyprolis prescribing information
• WHO — Model List of Essential Medicines

Further reading and regulatory routes

• Which country Kyprolis is sourced from, and why prices differ
• How to verify a medicine is genuine
• Why medicines cost less in Türkiye
• WHO falsified medicine alerts
• Named patient supply
• UAE import guide
• For healthcare professionals
• All medicine monographs

Related medicines

• Blincyto (blinatumomab)
• Padcev (enfortumab vedotin)
• Calquence (acalabrutinib)